Search | Clinical Trials Finder

Conditions: Estrogen Therapy
Interventions: Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy; Drug · Device
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 456,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Eden Prairie, Minnesota

Conditions: Breast Cancer
Interventions: polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 180
States / cities: Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more

Conditions: Women's Health
Interventions: Resistance Training; Behavioral
Lead sponsor: Southern Illinois University Edwardsville; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Edwardsville, Illinois

Conditions: Breast Cancer
Interventions: Outcomes4Me, Semi-structured interview; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions: testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 528
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more

Conditions: Coronary Heart Disease
Interventions: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 2,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2001
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Neoplasms, Osteoporosis
Interventions: Zoledronic Acid, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 43
States / cities: Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more

Conditions: Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp; Device · Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 25 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Conditions: Breast Cancer
Interventions: Lapatinib, Letrozole, Trastuzumab; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 70 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy; Procedure · Other · Genetic + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more

Conditions: Fertility, Contraception
Interventions: Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial, Postmenopause
Interventions: Estrogen therapy; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Anastrozole, AZD0530 (saracatinib), Placebo; Drug
Lead sponsor: Joyce Marie Slingerland, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Palo Alto, California • Miami, Florida

Conditions: Solid Tumors, Advanced Cancer
Interventions: Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions: Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia

Conditions: Endometrial Cancer
Interventions: Sodium Cridanimod, progestin therapy; Drug
Lead sponsor: Xenetic Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 25
States / cities: Burbank, California • Irvine, California • Los Angeles, California + 22 more

Conditions: Breast Cancer, Invasive Breast Cancer
Interventions: Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Covid19
Interventions: Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule; Other · Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18; Biological · Drug · Other + 2 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Resistance Training and Sex Hormone Concentrations During the Menstrual Cycle

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Heart and Estrogen-Progestin Replacement Study (HERS)

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Regulation of Cervical Mucus Secretion

Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

The Effects of Reproductive Hormones on Mood and Behavior

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Estradiol and Progesterone in Hospitalized COVID-19 Patients

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer